News
Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The ...
An NHS trust has agreed a three-year plan to cut up to £260m from its budget and break even. Under the plan, NHS Shropshire, ...
Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...
Apollo HealthCo clocked a revenue of ₹9,093 crore in FY25, growing 16% year-on-year. The platform delivered three successive ...
For the first time, 40-year-old Manmeet Bindra feels motivated to exercise and has set up a home gym, cleaned up her diet and ...
India is entering a new era of medical weight loss with the introduction of powerful drugs like Wegovy, and the growing off-label use of Ozempic and ...
The hot topic at Psychedelic Science Conference 2025 was the potential for treating PTSD with MDMA and magic mushrooms ...
Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...
India’s non-alcoholic beverage sector is projected to more than double to $88 billion by 2027. That’s a staggering 18% ...
India's clinical trial industry has surged into the top three globally, driven by regulatory reforms, affordability, vast ...
Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a ...
Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a fast-growing market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results